Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
SGX301 treatment response continues to demonstrate highly statistically significant improvement after 12 weeks of therapy
Response rate in patients receiving a total of 12 weeks treatment increased two and a half-fold
Reinforces positive SGX301 prima... Biopharmaceuticals, Oncology Soligenix, synthetic hypericin, cutaneous T-cell lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Lymphoma | Pharmaceuticals | Statistics | Study | T-cell Lymphoma